Macquarie Group Ltd. trimmed its holdings in shares of Heska Corp (NASDAQ:HSKA) by 5.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,592 shares of the medical research company’s stock after selling 147 shares during the quarter. Macquarie Group Ltd.’s holdings in Heska were worth $223,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. We Are One Seven LLC acquired a new stake in Heska in the fourth quarter valued at approximately $86,000. LS Investment Advisors LLC boosted its stake in Heska by 30.1% in the fourth quarter. LS Investment Advisors LLC now owns 1,133 shares of the medical research company’s stock valued at $98,000 after acquiring an additional 262 shares in the last quarter. Bank of Montreal Can boosted its stake in Heska by 11.7% in the fourth quarter. Bank of Montreal Can now owns 1,876 shares of the medical research company’s stock valued at $162,000 after acquiring an additional 196 shares in the last quarter. Municipal Employees Retirement System of Michigan acquired a new stake in Heska in the fourth quarter valued at approximately $168,000. Finally, Virtu Financial LLC acquired a new stake in Heska in the third quarter valued at approximately $223,000. 83.03% of the stock is currently owned by institutional investors.
Several brokerages have weighed in on HSKA. Sidoti downgraded shares of Heska from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 26th. BidaskClub upgraded shares of Heska from a “sell” rating to a “hold” rating in a research note on Wednesday, March 27th. ValuEngine downgraded shares of Heska from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Zacks Investment Research downgraded shares of Heska from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $109.00.
Shares of NASDAQ:HSKA traded down $2.05 on Thursday, hitting $79.57. 56,500 shares of the company were exchanged, compared to its average volume of 82,127. Heska Corp has a 1-year low of $71.50 and a 1-year high of $114.50. The company has a market capitalization of $613.80 million, a P/E ratio of 56.04 and a beta of 0.73.
Heska (NASDAQ:HSKA) last posted its earnings results on Tuesday, May 7th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.19. The company had revenue of $29.51 million during the quarter, compared to the consensus estimate of $35.21 million. Heska had a net margin of 4.59% and a return on equity of 9.87%.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Read More: Book Value Per Share in Stock Trading
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.